Mudcat, I really don't think that you understand what is and is not to be expected in the popular press articles. The NY Times article was in the "Science" section and was on Tamoxifen. As noted, even when the upcoming followup prevention trial pitting Tamoxifen against Evista was mentioned, there was no mention of LLY, Evista, or Raloxifene. The articles are NOT intended to present a list of compounds under development or companies developing them.
NO COMPANY was mentioned in the entire article, even though it was quite lengthy. NO COMPOUND was mentioned although many SERMs (Evista, Droloxifene, Idoxifene, CP-366,156, TSE424) being developed by several companies (LLY, PFE, AHP, SBH), and some other compounds (Targretin, Panretin) have chemopreventive properties and they synergize with Tamoxifen.
To expect Targretin, Panretin, or Ligand to be mentioned in such an article is extremely chavinistic, and not reality based. |
